Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

11%

1 of 9 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
5(55.6%)
Phase 4
1(11.1%)
N/A
1(11.1%)
Phase 2
1(11.1%)
Phase 3
1(11.1%)
9Total
Phase 1(5)
Phase 4(1)
N/A(1)
Phase 2(1)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT07066150Not ApplicableCompleted

A Clinical Evaluation of Marula-Derived Ceramide Cream on Skin Barrier Function Enhancement

Role: collaborator

NCT05898984Phase 1Completed

Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®

Role: collaborator

NCT03004417Phase 2Completed

Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD

Role: collaborator

NCT02765724Phase 1Completed

Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects

Role: collaborator

NCT03439072Phase 3Completed

G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes

Role: collaborator

NCT02807077Phase 1Completed

PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects

Role: collaborator

NCT02788721Phase 1Completed

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Female Subjects

Role: collaborator

NCT01808885Phase 1Completed

Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.

Role: collaborator

NCT01110356Phase 4Completed

Ferric Carboxymaltose Treatment to Improve Fatigue Symptoms in Iron-deficient Non-anaemic Women of Child Bearing Age

Role: collaborator

All 9 trials loaded